Literature DB >> 21851881

Diagnostic work-up and risk stratification in X-linked dilated cardiomyopathies caused by dystrophin defects.

Marta Diegoli1, Maurizia Grasso, Valentina Favalli, Alessandra Serio, Fabiana Isabella Gambarin, Catherine Klersy, Michele Pasotti, Emanuela Agozzino, Laura Scelsi, Alessandra Ferlini, Oreste Febo, Giovanni Piccolo, Luigi Tavazzi, Jagat Narula, Eloisa Arbustini.   

Abstract

OBJECTIVES: We sought to describe the diagnostic work-up, phenotype, and long-term evolution of dilated cardiomyopathy (DCM) associated with Dystrophin (DYS) defects.
BACKGROUND: X-linked DCM associated with DYS defects can be clinically indistinguishable from other types of DCM.
METHODS: The series comprises 436 consecutive male patients diagnosed with DCM. Patients underwent endomyocardial biopsy (EMB). Genetic testing employed multiplex polymerase chain reaction and multiple ligation dependent probe assay for deletions and direct sequencing of the 79 exons and flanking regions of the gene for point mutations or small rearrangements.
RESULTS: We identified DYS defects in 34 of 436 patients (7.8%) (onset age 34 ± 11 years, age range 17 to 54 years); 30 had proven X-linked inheritance. The 2 phenotypes included DCM with mild skeletal myopathy and/or increased serum creatine phosphokinase (n = 28) or DCM only (n = 6). The EMB showed defective dystrophin immunostain. The DYS defects consisted of 21 in-frame deletions and 11 out-of-frame deletions as well as 1 stop and 1 splice-site mutation. During a median follow-up of 60 months (interquartile range: 11.25 to 101.34 months) we observed 17 events, all related to heart failure (HF) (median event-free survival: 83.5 months). Eight patients (23%) underwent transplantation, and 9 (26%) died of HF while waiting for transplantation. Eight patients received an implantable cardioverter-defibrillator, although none had device intervention during a median follow-up of 14 months (interquartile range: 5 to 25 months). No patient died suddenly, suffered syncope, or developed life-threatening ventricular arrhythmias.
CONCLUSIONS: DYS-related DCM should be suspected in male patients with increased serum creatine phosphokinase (82%) and X-linked inheritance. The disease shows a high risk of end-stage HF but a lower risk of life-threatening arrhythmias.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21851881     DOI: 10.1016/j.jacc.2011.01.072

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  27 in total

Review 1.  Gene expression in spermiogenesis.

Authors:  H Tanaka; T Baba
Journal:  Cell Mol Life Sci       Date:  2005-02       Impact factor: 9.261

2.  [Ventricular tachycardia : Treatment and prognostic significance].

Authors:  Stephanie Fichtner; Stefan Kääb
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-12

3.  Familial dilated cardiomyopathy. Clinical and genetic characteristics.

Authors:  A Serio; N Narula; T Kodama; V Favalli; E Arbustini
Journal:  Herz       Date:  2012-12       Impact factor: 1.443

Review 4.  Inherited cardiomyopathies.

Authors:  Jeffrey A Towbin
Journal:  Circ J       Date:  2014-09-02       Impact factor: 2.993

Review 5.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

Review 6.  Treatment of dystrophin cardiomyopathies.

Authors:  Josef Finsterer; Linda Cripe
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

Review 7.  Heart transplantation in patients with dystrophinopathic cardiomyopathy: Review of the literature and personal series.

Authors:  Andrea Antonio Papa; Paola D'Ambrosio; Roberta Petillo; Alberto Palladino; Luisa Politano
Journal:  Intractable Rare Dis Res       Date:  2017-05

8.  Dystrophin genotype-cardiac phenotype correlations in Duchenne and Becker muscular dystrophies using cardiac magnetic resonance imaging.

Authors:  Animesh Tandon; John L Jefferies; Chet R Villa; Kan N Hor; Brenda L Wong; Stephanie M Ware; Zhiqian Gao; Jeffrey A Towbin; Wojciech Mazur; Robert J Fleck; Joshua J Sticka; D Woodrow Benson; Michael D Taylor
Journal:  Am J Cardiol       Date:  2015-01-15       Impact factor: 2.778

Review 9.  The MOGE(S) classification : A TNM-like classification for cardiomyopathies.

Authors:  E Şahan; S Şahan; M Karamanlıoğlu; M Gul; O Tufekcioğlu
Journal:  Herz       Date:  2016-01-25       Impact factor: 1.443

10.  Cardiac Disease Burden and Risk of Mortality in Hospitalized Muscular Dystrophy Patients.

Authors:  Ann R Punnoose; Jonathan R Kaltman; William Pastor; Robert McCarter; Jianping He; Christopher F Spurney
Journal:  Pediatr Cardiol       Date:  2016-06-17       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.